Lisocabtagene maraleucel (Breyanzi)

From - A Hematology Oncology Wiki
Jump to navigation Jump to search

Mechanism of action

From the NCI Drug Dictionary: A preparation of a defined ratio of CD4+ and CD8+ autologous T lymphocytes transduced with a lentiviral vector expressing a chimeric antigen receptor (CAR) containing an anti-CD19 single chain variable fragment (scFv) fused to the signaling domain of 4-1BB (CD137), the zeta chain of the TCR/CD3 complex (CD3-zeta), and a truncated form of the human epidermal growth factor receptor (EGFRt), with potential immunostimulating and antineoplastic activities. Upon intravenous administration, lisocabtagene maraleucel is directed to and induce selective toxicity in CD19-expressing tumor cells.

Toxicity management

Diseases for which it is established

Diseases for which it is used

History of changes in FDA indication

History of changes in EMA indication

History of changes in Health Canada indication

  • 2022-05-06: Initial notice of compliance

History of changes in PMDA indication

  • 2021-03-22: Initial approval

Patient Drug Information

Also known as

  • Code name: JCAR-017
  • Generic name: liso-cel
  • Brand name: Breyanzi